Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|October 7, 2014

FDA Releases Guidance on Critical Path Innovation Meetings

FDA outlines procedures for having a Critical Path Innovation Meeting with CDER.

FDA has released draft guidance on the purpose, scope, documentation, and administrative procedures for a Critical Path Innovation Meeting (CPIM). The guidance includes how to request such a CPIM meeting, which is the way the Center for Drug Evaluation and Research (CDER) and investigators from industry, academia, patient advocacy groups, and government can communicate to improve efficiency and success in drug development.

A CPIM may be used as a way for industry to discuss a methodology or technology with CDER so that CDER may identify gaps in existing knowledge that requesters might consider addressing in the course of their work. According to FDA, discussions and background information submitted through the CPIM are nonbinding on both FDA and CPIM requesters.

The guidance provides some examples of topics appropriate for a CPIM. It also describes information that should be provided to CDER in preparation for a meeting and potential outcomes from the CPIM.

Source: FDA


Related to this article

The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.